RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates the global radiopharmaceuticals market with an estimated market share of 41.2% in 2024. The region has strong presence of leading industry players as well as formidable healthcare infrastructure and research capabilities. Most of the globally recognized players in radiopharmaceuticals manufacturing operate out of the U.S. and have their headquarters located in the region. This allows them to cater to both domestic as well as international markets effectively. The presence of advanced nuclear medicine facilities, availability of sophisticated diagnostic equipment and growing adoption of PET and SPECT scans for clinical diagnosis and treatment monitoring can drive the market growth.

Asia Pacific region is projected to witness the fastest growth. Factors such as rising healthcare expenditure, growing geriatric population, increasing incidence of target diseases and presence of untapped opportunities drives the market growth in the region. China, India and Japan are anticipated to be the major revenue generators. While China and India are focused on providing radiopharmaceuticals at competitive prices, Japan is contributing through its technological innovations. Furthermore, developing healthcare infrastructure, rising medical tourism and favourable regulatory framework are attracting many global players to enter Asia Pacific markets through joint ventures, partnerships and acquisitions. However, lack of skilled professionals and price control regulations in some countries continue to can hamper the market growth.